文献速递泌尿生殖妇产影像MR

如何改进O-RADS MRI评分以评估含囊性成分的附件肿块

How to improve O-RADS MRI score for rating adnexal masses with cystic component?
PubMed 文献 · Eur Radiol · 2022-03-24

本研究回顾性查询EURAD数据库,纳入585例患者779个盆腔肿块,评估O-RADS MRI对含囊性成分附件肿块的诊断效能,并探索囊性成分相关MRI特征。O-RADS MRI评分诊断效能AUC为0.944(95%CI 0.922-0.961),联合囊性成分ADC均值>1.69、病灶>75 mm及扩散加权低信号后AUC提升至0.958(95%CI 0.938-0.973)。

要点

  • O-RADS MRI评分联合囊性成分ADC均值>1.69、病灶>75 mm及DWI低信号可提高恶性预测效能(AUC 0.958 vs 0.944)。
  • 囊性成分ADC均值>1.69(OR=7)、分房数≥3(OR=5.16)、病灶>75 mm(OR=4.40)与恶性相关。
  • O-RADS MRI评分4且囊性成分ADC<1.69并伴DWI低信号的病灶恶性风险几乎为0%。

核心结论

  • 囊性成分分析可能提高O-RADS MRI评分对附件囊性肿块的诊断效能。

研究设计与样本

  • 回顾性查询EURAD数据库,纳入585例患者779个盆腔肿块,以组织学为参考标准;1名初级和13名放射科医生在不知病理诊断的情况下独立阅片。

关键影像表现/征象

  • 囊性成分T1加权低信号(评分1、2或3)、T2加权高信号(评分4或5)及扩散加权低信号与恶性相关。
  • 囊性成分ADC均值>1.69、分房数≥3、病灶>75 mm、厚壁存在与恶性显著相关。

诊断标准与关键数值

  • O-RADS MRI评分诊断效能AUC为0.944(95%CI 0.922-0.961)。
  • O-RADS MRI评分≥4联合囊性成分ADC均值>1.69、病灶>75 mm及扩散加权低信号后AUC提升至0.958(95%CI 0.938-0.973)。
  • 囊性成分ADC均值>1.69(OR=7)、分房数≥3(OR=5.16)、病灶>75 mm(OR=4.40)、厚壁(OR=3.59)、T2加权高信号评分4或5(OR=3.30)、T1加权低信号评分1、2或3(OR=3.45)、扩散加权低信号(OR=2.12)与恶性相关。

临床应用与阅片要点

  • 含囊性成分的附件肿块若O-RADS MRI评分4且囊性成分ADC<1.69并伴扩散加权低信号,恶性风险几乎为0%。
  • 评估附件囊性肿块时,可关注囊性成分的ADC均值、分房数、病灶大小、壁厚度及T1/T2/DWI信号特征以辅助O-RADS MRI评分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To test the performance of the Ovarian-Adnexal Reporting Data System (O-RADS) MRI in characterizing adnexal masses with cystic components and to test new specific MRI features related to cystic components to improve the ability of the O-RADS MRI score to stratify lesions according to their risk of malignancy.

METHODS: The EURopean ADnexal study (EURAD) database was retrospectively queried to identify adnexal masses with a cystic component. One junior and 13 radiologists independently reviewed cases blinded to the pathological diagnosis. For each lesion, the size of the whole lesion, morphological appearance, number of loculi, presence of a thickened wall, thickened septae, signal intensity of the cystic components on T1-weighted/T2-weighted/diffusion weighted, mean value of the apparent diffusion coefficient, and O-RADS MRI score were reported. Univariate and multivariate logistic regression analysis was performed to determine significant features to predict malignancy.

RESULTS: The final cohort consisted of 585 patients with 779 pelvic masses who underwent pelvic MRI to characterize an adnexal mass(es). Histology served as the standard of reference. The diagnostic performance of the O-RADS MRI score was 0.944, 95%CI [0.922-0.961]. Significant criteria associated with malignancy included an O-RADS MRI score ≥ 4, ADCmean of cystic component > 1.69, number of loculi > 3, lesion size > 75 mm, the presence of a thick wall, and a low T1-weighted, a high T2-weighted, and a low diffusion-weighted signal intensity of the cystic component. Multivariate analysis demonstrated that an O-RADS MRI score ≥ combined with an ADC mean of the cystic component > 1.69, size > 75 mm, and low diffusion-weighted signal of the cystic component significantly improved the diagnostic performance up to 0.958, 95%CI [0.938-0.973].

CONCLUSION: Cystic component analysis may improve the diagnosis performance of the O-RADS MRI score in adnexal cystic masses.

KEY POINTS: • O-RADS MRI score combined with specific cystic features (area under the receiving operating curve, AUROC = 0.958) improves the diagnostic performance of the O-RADS MRI score (AUROC = 0.944) for predicting malignancy in this cohort. • Cystic features that improve the prediction of malignancy are ADC mean > 1.69 (OR = 7); number of loculi ≥ 3 (OR = 5.16); lesion size > 75 mm (OR = 4.40); the presence of a thick wall (OR = 3.59); a high T2-weighted signal intensity score 4 or 5 (OR = 3.30); a low T1-weighted signal intensity score 1, 2, or 3 (OR = 3.45); and a low diffusion-weighted signal intensity (OR = 2.12). • An adnexal lesion with a cystic component rated O-RADS MRI score 4 and an ADC value of the cystic component < 1.69 associated with a low diffusion-weighted signal, has virtually a 0% risk of malignancy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Assouline, Dabi, Jalaguier-Coudray, et al. How to improve O-RADS MRI score for rating adnexal masses with cystic component? Eur Radiol. 2022. PMID: 35332409. doi:10.1007/s00330-022-08644-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。